Gilead Sciences announced results from ION-4, a Phase 3 study evaluating Harvoni (ledipasvir 90mg/sofosbuvir 400mg) for the treatment of genotypes 1 or 4 chronic hepatitis C virus (HCV) infection among patients co-infected with HIV.
Bristol-Myers Squibb Company announced results from ALLY-2, a Phase 3 trial evaluating the use of daclatasvir and sofosbuvir for the treatment of patients with chronic hepatitis C virus (HCV) co-infected with HIV.
The Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) has issued new recommendations on immunizations, including influenza, serogroup B meningococcal, and human papillomavirus (HPV) vaccination.
Lenvima (lenvatinib; Eisai) is now available through two specialty pharmacies, Accredo and Biologics Inc. for the treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC).
The Food and Drug Administration (FDA) has approved Liletta (levonorgestrol-releasing intrauterine system; Actavis and Medicines360) for use by women to prevent pregnancy for up to three years.